
## Anthony Fernandez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9331583/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms. Journal of Cutaneous Pathology, 2022, 49, 220-230.	1.3	21
2	Calciphylaxis in uraemic and nonuraemic settings: clinical risk factors and histopathological findings. Clinical and Experimental Dermatology, 2022, 47, 700-708.	1.3	3
3	TNFR2 Depletion Reduces Psoriatic Inflammation in Mice by Downregulating Specific Dendritic Cell Populations in Lymph Nodes and Inhibiting IL-23/IL-17 Pathways. Journal of Investigative Dermatology, 2022, 142, 2159-2172.e9.	0.7	4
4	Analysis of clinical and serologic predictors of response to extracorporeal photopheresis therapy in cutaneous T ell lymphoma patients. Photodermatology Photoimmunology and Photomedicine, 2022, 38, 600-603.	1.5	0
5	A United States expert consensus to standardise definitions, followâ€up, and treatment targets for extraâ€intestinal manifestations in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2022, 55, 1179-1191.	3.7	7
6	Common skin signs of COVID-19 in adults: An update. Cleveland Clinic Journal of Medicine, 2022, 89, 161-167.	1.3	10
7	Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: <i>post hoc</i> analysis of 5â€year data from <scp>reSURFACE</scp> 1 and <scp>reSURFACE</scp> 2. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1774-1783.	2.4	7
8	Routine rescreening for latent tuberculosis has low utility in patients with chronic immune-mediated inflammatory diseases treated with biologics: A single-center, retrospective cohort study. Journal of the American Academy of Dermatology, 2022, 87, 841-843.	1.2	3
9	Breakthrough <scp>SARS</scp> – <scp>CoV</scp> â€2 Infections in Patients With <scp>Immuneâ€Mediated</scp> Disease Undergoing B Cell–Depleting Therapy: A Retrospective Cohort Analysis. Arthritis and Rheumatology, 2022, 74, 1906-1915.	5.6	23
10	Characteristics of hospitalized dermatomyositis patients with underlying malignancy: a nationally representative retrospective cohort study. Archives of Dermatological Research, 2021, 313, 473-482.	1.9	4
11	Safety of trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia prophylaxis in patients taking methotrexate. Journal of the American Academy of Dermatology, 2021, 84, 166-168.	1.2	5
12	Fairness and transparency in medical journals. Journal of the American Academy of Dermatology, 2021, 85, 31-32.	1.2	1
13	Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening?. Annals of Translational Medicine, 2021, 9, 432-432.	1.7	16
14	Systematic Review: Sweet Syndrome Associated with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, 1864-1876.	1.3	11
15	Development of sacral/buttock retiform purpura as an ominous presenting sign of COVID â€19 and clinical and histopathologic evolution during severe disease course. Journal of Cutaneous Pathology, 2021, 48, 1166-1172.	1.3	6
16	Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach. Seminars in Arthritis and Rheumatism, 2021, 51, 593-600.	3.4	13
17	Insidious-Onset Indurated Plaques on the Shins. Dermatopathology (Basel, Switzerland), 2021, 8, 185-189.	1.5	1
18	Developing classification criteria for skinâ€predominant dermatomyositis: the Delphi process. British Journal of Dermatology, 2020, 182, 410-417.	1.5	25

ANTHONY FERNANDEZ

#	Article	IF	CITATIONS
19	TNF-α inhibitor–induced psoriasis: AÂdecade of experience at the Cleveland Clinic. Journal of the American Academy of Dermatology, 2020, 83, 1590-1598.	1.2	38
20	Erosive pustular dermatosis of the scalp associated with Sirolimus. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e15-e16.	2.4	2
21	Disseminated discoid lupus erythematosus mimicking Degos disease. Australasian Journal of Dermatology, 2020, 61, e114-e116.	0.7	0
22	Utility of repeat latent tuberculosis testing with the Quanti <scp>FERON</scp> ― <scp>TB</scp> Gold test in patients with psoriasis treated with tumour necrosis factorâ€î± inhibitors at a single U.S. institution. British Journal of Dermatology, 2020, 182, 800-802.	1.5	13
23	Utility of the neutrophil/lymphocyte ratio for predicting malignancy risk and prognosis in patients with dermatomyositis. Clinical and Experimental Dermatology, 2020, 45, 471-473.	1.3	1
24	Diagnoses of hospitalized patients with skin abnormalities prompting biopsy by consulting dermatologists: A 3â€year review from a tertiary care center. Journal of Cutaneous Pathology, 2020, 47, 346-356.	1.3	5
25	Linear Immunoglobulin A Bullous Dermatosis Associated With Ulcerative Colitis. American Journal of Gastroenterology, 2020, 115, 1384-1384.	0.4	1
26	The skin myositis Delphi group puts the details in â€~skinâ€predominant' dermatomyositis. British Journal of Dermatology, 2020, 182, 274-275.	1.5	0
27	Reply to: "Evidence-based guidelines for tuberculosis screening before biologic treatment initiation― Journal of the American Academy of Dermatology, 2020, 83, e27-e28.	1.2	0
28	Large sacral/buttocks ulcerations in the setting of coagulopathy: A case series establishing the skin as a target organ of significant damage and potential morbidity in patients with severe COVID â€19. International Wound Journal, 2020, 17, 2033-2037.	2.9	16
29	An observational study: skin biopsy tissue can remain out of formalin and still retain its ability to make an accurate histologic diagnosis. Journal of the American Academy of Dermatology, 2020, 85, 1333-1336.	1.2	Ο
30	Cerebral Microhemorrhage and Purpuric Rash in COVID-19: The Case for a Secondary Microangiopathy. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 105111.	1.6	14
31	QuantiFERONâ€TB Gold conversion is not uncommon in patients with psoriasis undergoing antiâ€ŧumour necrosis factorâ€Î± therapy: reply from the author. British Journal of Dermatology, 2020, 183, 978-978.	1.5	0
32	Creation and Validation of Classification Criteria for Discoid Lupus Erythematosus. JAMA Dermatology, 2020, 156, 901.	4.1	18
33	Family history of psoriasis, psychological stressors, and tobacco use are associated with the development of tumor necrosis factor-î± inhibitor-induced psoriasis: A case-control study. Journal of the American Academy of Dermatology, 2020, 83, 1599-1605.	1.2	10
34	Conversion to positive latent tuberculosis infection status is low in patients with hidradenitis suppurativa taking biologic medications. Journal of the American Academy of Dermatology, 2020, 83, 246-248.	1.2	6
35	Evaluation of the Effectiveness and Tolerability of Mycophenolate Mofetil and Mycophenolic Acid for the Treatment of Morphea. JAMA Dermatology, 2020, 156, 521.	4.1	24
36	Cutaneous adverse effects of biologic medications. Cleveland Clinic Journal of Medicine, 2020, 87, 288-299.	1.3	11

ANTHONY FERNANDEZ

#	Article	IF	CITATIONS
37	Skin manifestations of COVID-19. Cleveland Clinic Journal of Medicine, 2020, , .	1.3	59
38	Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma. Clinical and Experimental Dermatology, 2019, 44, 113-115.	1.3	11
39	Histopathologic correlation of highâ€risk MelaFind TM lesions: a 3â€year experience from a highâ€risk pigmented lesion clinic. International Journal of Dermatology, 2019, 58, 569-576.	1.0	3
40	Amyopathic dermatomyositis – a â€~feelâ€good' dermatology story. British Journal of Dermatology, 2019, 180, 974-974.	1.5	0
41	Adverse Cutaneous Reactions of Common Biologic Medications for Rheumatic Diseases. Current Treatment Options in Rheumatology, 2019, 5, 290-312.	1.4	0
42	Connective Tissue Disease. Dermatologic Clinics, 2019, 37, 37-48.	1.7	17
43	Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash. Oncologist, 2019, 24, 4-8.	3.7	7
44	Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus—An Ongoing Need for International Consensus and Collaborations. Journal of Investigative Dermatology, 2019, 139, 270-276.	0.7	18
45	Malignancy-associated dermatomyositis: Retrospective case–control study from a single tertiary care center. Journal of the American Academy of Dermatology, 2018, 79, 152-155.	1.2	5
46	Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis. Clinical and Experimental Dermatology, 2018, 43, 906-912.	1.3	18
47	Comparison of US patient, rheumatologist, and dermatologist perceptions of psoriatic disease symptoms: results from the DISCONNECT study. Arthritis Research and Therapy, 2018, 20, 102.	3.5	15
48	Seronegative dermatomyositis presenting with features of antiâ€MDA5 subtype. Journal of Cutaneous Pathology, 2018, 45, 851-854.	1.3	3
49	Direct immunofluorescence testing in vasculitis—A single institution experience with Henochâ€5chönlein purpura. Journal of Cutaneous Pathology, 2018, 45, 16-22.	1.3	8
50	Biologic Therapy in the Treatment of Chronic Skin Disorders. Immunology and Allergy Clinics of North America, 2017, 37, 315-327.	1.9	2
51	Updated recommendations on the use of hydroxychloroquine in dermatologic practice. Journal of the American Academy of Dermatology, 2017, 76, 1176-1182.	1.2	44
52	Eosinophils are rare in biopsy specimens of psoriasis vulgaris. Journal of Cutaneous Pathology, 2017, 44, 1027-1032.	1.3	15
53	Low-Dose Naltrexone Treatment of Familial Benign Pemphigus (Hailey-Hailey Disease). JAMA Dermatology, 2017, 153, 1015.	4.1	36
54	Reply to: "High risk category for early annual ophthalmology screening on hydroxychloroquine― Journal of the American Academy of Dermatology, 2017, 77, e173.	1.2	0

#	Article	IF	CITATIONS
55	Epidermal multinucleated keratinocytes: a histopathologic clue to dermatitis artefacta. Journal of Cutaneous Pathology, 2016, 43, 880-883.	1.3	14
56	Dermatology consultations significantly contribute quality to care of hospitalized patients: a prospective study of dermatology inpatient consults at a tertiary care center. International Journal of Dermatology, 2016, 55, e547-51.	1.0	37
57	Sarcoidosis following successful treatment of pemphigus vulgaris with rituximab: a rituximab-induced reaction further supporting B-cell contribution to sarcoidosis pathogenesis?. Clinical and Experimental Dermatology, 2016, 41, 413-416.	1.3	22
58	Langerhans cell collections, but not eosinophils, are clues to a diagnosis of allergic contact dermatitis in appropriate skin biopsies. Journal of Cutaneous Pathology, 2016, 43, 498-504.	1.3	25
59	Erythematous and edematous plaques on the bilateral extremities in an immunocompromised patient. International Journal of Dermatology, 2016, 55, e59-61.	1.0	2
60	Clinically amyopathic dermatomyositis: clinical features, response to medications and malignancyâ€associated risk factors in a specific tertiaryâ€careâ€centre cohort. British Journal of Dermatology, 2016, 174, 158-164.	1.5	37
61	Pagetoid Spitz nevi: clinicopathologic characterization of a series of 12 cases. Journal of Cutaneous Pathology, 2016, 43, 932-939.	1.3	8
62	Erythematous Papules on the Forearms. JAMA Dermatology, 2015, 151, 891.	4.1	3
63	A refractory rash in a seborrheic distribution. Lancet, The, 2015, 385, 1777.	13.7	0
64	Impact of smoking on response to systemic treatment in patients with psoriasis: a retrospective case-control study. British Journal of Dermatology, 2015, 172, 428-436.	1.5	15
65	Intravenous immunoglobulin for treatment of dermatomyositis-associated dystrophic calcinosis. Journal of the American Academy of Dermatology, 2015, 73, 174-176.	1.2	18
66	Parvovirus mimicking acute HIV infection. Cleveland Clinic Journal of Medicine, 2015, 82, 481-482.	1.3	2
67	Dermatology update: The dawn of targeted treatment. Cleveland Clinic Journal of Medicine, 2015, 82, 309-320.	1.3	6
68	In Reply: The role of sentinel lymph node biopsy after excision of melanomas. Cleveland Clinic Journal of Medicine, 2015, 82, 479-480.	1.3	0
69	Kasabach– <scp>M</scp> erritt phenomenon in an adult man with a tufted angioma and cirrhosis responding to radiation, bevacizumab, and prednisone. International Journal of Dermatology, 2014, 53, 1165-1176.	1.0	11
70	Psoriasis improvement after bariatric surgery. Surgery for Obesity and Related Diseases, 2014, 10, 1155-1159.	1.2	43
71	FISH for MYC amplification and antiâ€MYC immunohistochemistry: useful diagnostic tools in the assessment of secondary angiosarcoma and atypical vascular proliferations. Journal of Cutaneous Pathology, 2012, 39, 234-242.	1.3	111
72	Histopathologic analysis of dermal lymphatic alterations in chronic venous insufficiency ulcers using D2-40. Journal of the American Academy of Dermatology, 2011, 64, 1123.e1-1123.e12.	1.2	8

#	Article	IF	CITATIONS
73	The use of i.v. IG therapy in dermatology. Dermatologic Therapy, 2007, 20, 288-305.	1.7	29